Document Detail


The new genetics: will it pay its way?
MedLine Citation:
PMID:  2883498     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The number of genetic disorders detectable antenatally by the use of DNA probes has risen rapidly. The demand for diagnosis and termination of affected pregnancies in high-risk families is likely to increase as tests become more accurate and widely known. Each Regional Health Authority (RHA) must therefore urgently compare any financial savings to be made from a DNA diagnostic service with the cost of setting up and running a laboratory. There are great difficulties in conducting a formal cost-benefit analysis, but the pressing need for a cost appraisal made a more limited cost-savings approach necessary. This paper uses a broad-brush approach for all disorders and known costs for inpatient hospital care only. Despite the limitations of the method, in the two regions studied (North West and South East Thames) there would be clear savings at hospital level if a DNA screening laboratory were set up in each region. Funds released from treatment of genetic disorders could be used for other purposes. There are benefits to the families concerned, social service and educational savings, and other health service savings not considered here. On hospital costs alone there are benefits from the programme and wider consideration will make it more cost-effective. Once a programme is set up, new developments will make it even more cost-effective. It is concluded that RHAs should attach high priority to the setting up of such laboratories.
Authors:
J C Chapple; R Dale; B G Evans
Related Documents :
8272918 - The german health care system: model or mirage?
12291658 - A primer for accessing and using electronic communications technology.
16223968 - Mental health-related drug utilization among older adults: prevalence, trends, and costs.
1131608 - Cost-benefit analysis of long-term haemodialysis for chronic renal failure.
23509888 - Assessment of voluntary counseling and testing service utilization and associated facto...
22017278 - Non-clinical and extra-legal influences on decisions about compulsory admission to psyc...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Lancet     Volume:  1     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  1987 May 
Date Detail:
Created Date:  1987-06-24     Completed Date:  1987-06-24     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1189-92     Citation Subset:  AIM; E; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cost-Benefit Analysis
Cystic Fibrosis / diagnosis
DNA / analysis
Female
Genetic Diseases, Inborn* / diagnosis,  economics
Genetic Testing*
Great Britain
Hemophilia A / diagnosis
Heterozygote Detection
Humans
Models, Theoretical
Pregnant Women
Prenatal Diagnosis
Chemical
Reg. No./Substance:
9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Are hospital services rationed in New Haven or over-utilised in Boston?
Next Document:  Risk of unexplained stillbirth at different gestational ages.